HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Eric Lim Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lim, E. Search for Related Content PubMed PubMed Citation Articles by Lim, E. Related Collections Extracorporeal circulation Related Article

---

Original Articles: Adult Cardiac

Invited Commentary

Department of Thoracic Surgery, Royal Brompton Hospital, Sydney St, London, SW3 6NP United Kingdom

(Email: e.lim@rbht.nhs.uk).

The first 20% of the full text of this article appears below.

In relation to current expenditure on research to improve outcomes after coronary surgery and the costs of patient care, it is unlikely that any new discovery will achieve a better cost–benefit ratio than postoperative aspirin prescription at today's prices. Because aspirin is widely available as a generic drug, free from patent and no longer associated with corporate branding of a single multi-national pharmaceutical giant, it has certainly suffered from lack of commercially funded research and notable absence of marketing, rendering it the frumpy cousin (in accordance with a general rule in life) to the more glamorous, . . . [Full Text of this Article]

Related Article

Risk Stratification After Coronary Artery Bypass Surgery by a Point-of-Care Test of Platelet Function

Stefano Bevilacqua, Al Assal Alkodami, Elisabetta Volpi, Alfredo Giuseppe Cerillo, Sergio Berti, Mattia Glauber, and Jacopo Gianetti
Ann. Thorac. Surg. 2009 87: 496-502. [Abstract] [Full Text] [PDF]